Phosphodiesterase 4 PDE 4 Inhibitors - Biotech, Pharma and Life Science Channel
Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for diseases including chronic obstructive pulmonary disease. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Unfortunately, however many PDE-4 inhibitors have failed in early development due to low therapeutic ratios.
Several PDE-4 inhibitors have advanced to late stage clinical development or under regulatory review for treatment of pulmonary or inflammatory bowel diseases. Other inflammatory disease for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, multiple sclerosis and allergic rhinitis. Age-associated memory impairment and Alzheimer’s disease are also studied clinically as indications for PDE-4 inhibitors.
News Articles
SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacriti...
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field,...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the effects of the painkiller diclofenac on the heart and circulation when given systemically (b...
Long-term apremilast 'effective' in psoriatic arthritis
A novel drug called apremilast appears to be effective when used for extended periods of time to treat psoriatic arthritis, according to phase-III clinical trial data presented at the annual congress...
NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today an...
rEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant form of hu...
The Angeles Clinic and Research Institute presented groundbreaking new data on “Clinical Activity, Safety and Biomarkers of MPDL3280A, an Engineered PD-L1 Antibody in Pat...
Turkey's Hepatitis C Virus Drug Market Will More Than Triple by 2017
BURLINGTON, Mass., June 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017,...
LAUSANNE, Switzerland, June 4, 2013 /PRNewswire/ -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescrip...
Amakem to Present at Jefferies Global Healthcare Conference
DIEPENBEEK, Belgium, June 3, 2013 /PRNewswire/ -- Amakem NV, a clinical stage ophthalmology company, today announces that Dr. Jack Elands, CEO, will present at the Jefferies 2013 Global Healthcare Co...
Events
Diabetes: Secondary Complications, Regulation and Innovation Conference
SMi is very proud to present our 11th conference focusing on Diabetes and metabolic disorders taking place on 1st and 2nd Oct 2013, London.
Companies
The Angeles Clinic and Research Institute
âThe Angeles Clinic and Research Instituteâs mission is to advance cancer care through groundbreaking research and delivering innovative therapeutic options to al...
DOV is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. DOV has previously funded drug development and disco...
Onconova, based in Newtown, PA and Lawrenceville, NJ, discovers and develops novel patent- protected small molecule therapeutic agents for cancer, radiation protection and hematol...
Enanta Phatmaceuticals ARE A RESEARCH AND DEVELOPMENT-FOCUSED BIOTECHNOLOGY COMPANY that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in t...
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase...
Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targete...
Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene h...
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The...
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...
Angion Biomedica is a biopharmaceutical company founded in 1998 focused on discovery and development of drugs that harness the bodyâs protective, reparative and regenerative...
Clinical Trials
The purpose of this research study is to: 1) Determine the highest dose of the drug vorinostat that can be given safely in combination with carboplatin and gemcitabine and 2) determine how...
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
The purpose of this pilot trial is to determine whether a conversion from calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and sirolimus i...
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
HSP90 inhibition is a potentially new targeted drug modality in the treatment of HER2 positive, trastuzumab refractory breast cancer. Little is known about the pharmacodynamics of HSP90 in...
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effecti...
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Imatinib mesylate is an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular...
Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?
Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challen...
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action b...
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
The main aim of the study is to investigate the combined effects of using anabolic steroids and protease inhibitors on fat metabolism and body composition of People Living with HIV/AIDS....
Statins in Proteinuric Nephropathies
End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have increased morbidity and mortality mostly because of a dramatic excess of cardiovascular disease. Thus,...
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Proton pump inhibitors (PPIs) are mainly metabolized in the liver by CYP2C19, one of the cytochrome P450 isoenzymes, which shows a genetic polymorphism associated with enzyme activities. T...
PubMed Articles
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
The majority of human cancers harbour mutations promoting activation of the Akt protein kinase, and Akt inhibitors are being evaluated in clinical trials. An important question concerns the understand...
Engagement of NKG2D and DNAX accessory molecule-1 (DNAM-1) receptors on lymphocytes plays an important role for anticancer response and represents an interesting therapeutic target for pharmacological...
Potent, reversible inhibition of the cytochrome P450 CYP2C9 isoform was observed in a series of urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. This unwanted property was su...
A novel series of indole/indazole-aminopyrimidines was designed and synthesized with an aim to achieve optimal potency and selectivity for the c-Jun kinase family or JNKs. Structure guided design was...
1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble epoxide hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved t...
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is current...
Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening.
Through structure-based virtual screening, some dozen of benzene sulfonamides with novel scaffolds are identified as potent inhibitors against carbonic anhydrase (CA) IX with IC50 values ranging from...
The synthesis and structure-activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon ce...
Benzobisthiazole derivatives were identified as novel helicase inhibitors through high throughput screening against purified Staphylococcus aureus (Sa) and Bacillus anthracis (Ba) replicative helicase...
Caffeic acid derivatives: A new type of influenza neuraminidase inhibitors.
Recently, many natural products, especially some plant-derived polyphenols have been found to exert antiviral effects against influenza virus and show inhibitory activities on neuraminidases (NAs). In...
Videos
PDE4 inhibitors have little effect on quality of life in COPD patients
NEW YORK (Reuters Health) -- In terms of quality of life for patients with COPD, the improvements in lung function and exacerbation frequency produced by pho...
Medical and Biotech [MESH] Definitions
Taxodium
A plant genus of the family TAXODIACEAE. Members contain taxodione and taxodone, which are diterpenoid quinone methide tumor inhibitors.
Huperzia
A plant genus of the family LYCOPODIACEAE. Members contain huperzine, one of the CHOLINESTERASE INHIBITORS.
Angiostatins
Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity.
Phosphodiesterase I
A phosphoric diester hydrolase that removes 5'-nucleotides from the 3'-hydroxy termini of 3'-hydroxy-terminated OLIGONUCLEOTIDES. It has low activity towards POLYNUCLEOTIDES and the presence of 3'-phosphate terminus on the substrate may inhibit hydrolysis.
Pregnancy-associated Alpha 2-macroglobulins
Large (>160 kDa) glycoproteins with electrophoretic mobility of ALPHA-GLOBULINS, found in high concentration in the plasma of pregnant women but also in a number of species including mouse, rat, and others (ALPHA-MACROGLOBULINS). In humans, they are always present in the circulation and are nonspecific inhibitors of PROTEINASES, similar to COMPLEMENT PROTEINS (C3; C4; C5).
